DISTINCTIONS IN LYMPHOCYTE RESPONSES
More interleukin 15 (IL-15) than IL-2 was needed to generate comparable proliferative responses by phytohaemagglutinin (PHA) blasts and Tf-1b cells expressing high affinity and intermediate affinity IL-2 receptor (IL-2R) complexes, respectively. The focus of these experiments was to determine the contribution of the shared IL-2 and IL-15 receptor components to these dose-response differences. Some of this difference can be attributed to the role of the IL-2Rb chain, in that HuMikb1, a monoclonal antibody recognizing the IL-2Rb chain, blocks 92.2 2 2.5% (mean 2 SE) of the IL-2 proliferative response by Tf-1b cells but only inhibits 57.9 2 3.7% of the IL-15 response, indicating that IL-2 and IL-15 may physically utilize the IL-2Rb chain differently. Monoclonal antibody 341, which recognizes IL-2Rb but does not inhibit IL-2 binding to the IL-2Rb chain, blocks 35.4 2 2.3% of IL-15-stimulated proliferation of PHA blasts, while not affecting the IL-2-stimulated proliferation. Finally, although HuMikb1 does not inhibit IL-2 responses by PHA blasts bearing high affinity IL-2 receptors, HuMikb1 does block IL-15-stimulated proliferation by these same cells bearing high affinity IL-15 receptors (88.5 2 1.6% inhibition). This indicates that the role of IL-15Ra in the high affinity IL-15R complex is distinct from that of IL-2Ra in the high affinity IL-2R complex. Overall, these studies show that the physical interactions of the IL-2Rbg c complex with IL-2 are different than the interactions with IL-15.
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Interleukin 15 (IL-15) and IL-2 share several functional activities, including the ability to activate proliferation of T cells, B cells and NK cells, as well as lytic activity of NK cells. [1] [2] [3] [4] While most cell types that respond to IL-2 also respond to IL-15, a greater dose of IL-15 is often required to achieve the same level of response. One hypothesis that could account for these quantitative distinctions is that the different dose-response relationships for IL-2 and IL-15 might result from functional differences between the IL-2 and IL-15 molecules, or differences in their physical interaction with their respective receptor complexes.
The IL-2 receptor (IL-2R) complex includes three transmembrane glycoproteins: the 55-kDa IL-2Ra chain, the 70-75-kDa IL-2Rb chain and the 64-kDa g c chain. [5] [6] [7] [8] The high affinity IL-2R (K d = 2-50 pM) consists of an abg c heterotrimeric complex and is expressed on activated T cells. These cells express an excess of IL-2Ra chains which bind IL-2 with low affinity (K d = 2-20 nM), so that cells expressing all three IL-2R components exhibit both high (abg c receptor complexes) and low (IL-2Ra monomers) affinity binding. Cells expressing IL-2Rb and g c , but not IL-2Ra chains, exhibit intermediate affinity binding (K d = 0.5-2 nM) to IL-2. [5] [6] [7] [8] The IL-15R complex shares two subunits in common with the IL-2R complex. The intermediate affinity human IL-15R consists of IL-2Rb and g c (K d = 0.27-2.5 nM). 4, 9 Both the IL-2 and IL-15 receptor complexes need both IL-2Rb and g c to support signal transduction; 10, 11 however, a degree of specificity may be afforded by the contributions of each unique alpha chain, the IL-2Ra and IL-15Ra molecules, respectively. The IL-15Ra chain is a 58-60-kDa protein which shares structural similarity with the IL-2Ra chain, but differs from the IL-2Ra chain in that it is able to bind IL-15 with high affinity (K d = 10 − 11 M). 9, 12 Conversely, IL-2Ra alone binds to IL-2 with low affinity (K d = 10 − 8 M). The IL-2Ra and IL-15Ra chains do not possess signalling capabilities. In order to explore more fully the hypothesis that quantitative differences in IL-2 and IL-15 proliferative  responses are due to distinct extracellular interactions  with their shared receptor components, proliferative  responses by phytohaemagglutinin (PHA) blasts  expressing high affinity IL-2R complexes, and Tf-1b  cells expressing intermediate affinity IL-2R complexes were compared in the presence of antibodies against the IL-2Ra or IL-2Rb chains. In addition, responses of these cells to F42K, an IL-2 variant which does not bind to the IL-2Ra chain, were compared with responses to IL-15, as both these cytokines use the IL-2Rb and g c subunits, but not the IL-2Ra subunit.
RESULTS

IL-15 is less potent than IL-2 in stimulating proliferation of cells bearing either high affinity IL-2R or intermediate affinity IL-2R
Initial studies examined proliferative responses induced by IL-2 or IL-15 of PBMC from healthy donors that were first activated in vitro with PHA. These PHA blasts consisted of a heterogeneous population of lymphocytes which was at least 95% CD3 + as measured by flow cytometry (data not shown), indicating that these cells were predominantly activated T cells expressing high affinity IL-2 receptors. [5] [6] [7] PHA blasts were incubated with increasing concentrations of IL-2, IL-15 or F42K, an IL-2 variant which does not bind to the IL-2Ra subunit. Previous reports have shown that IL-2 and F42K stimulate  comparable responses in cells expressing intermediate  affinity IL-2 receptors, while F42K binds to and  stimulates high affinity IL-2 receptors less effectively  than does IL-2. 17-19 All three cytokines stimulated proliferation of PHA blasts (Fig. 1A) , but different concentrations of each cytokine were required to reach a comparable level of [ 3 H]thymidine incorporation. We found that IL-2 stimulated proliferation of PHA blasts most effectively, followed by F42K, and finally IL-15. For IL-2, the effective concentration needed to achieve a 50% maximal response (EC 50 , mean 2 SE) was 60.8 2 43 pM (n = 4); for F42K the EC 50 = 992 2 263 pM (n = 4), and for IL-15 the EC 50 = 6.13 2 0.54 nM (n = 4) ( Table 1 ). The mean EC 50 value for each cytokine was significantly different from each of the other cytokines, with P Q 0.0005 in all cases.
To compare IL-2 and IL-15 responses in a cell line which expresses intermediate affinity rather than high affinity IL-2R complexes, the Tf-1b myelomonocytic cell line was used. These cells express g c molecules endogenously and express the IL-2Rb chain from a retroviral vector.
14 Unlike PHA blasts, Tf-1b cells do (Fig. 1B) . The EC 50 (mean 2 SE) was 22, 23 Indeed, IL-2-stimulated proliferation of Tf-1b cells is completely abrogated by HuMikb1 ( Fig. 2A) . In contrast, HuMikb1 only inhibits approximately 65% of the response to IL-15 by Tf-1b cells (Fig. 2B) . One hypothesis to account for this observation is that IL-15 may interact with the IL-2Rb chain in a different region of the IL-2Rb molecule which is not blocked by the HuMikb1 antibody, and is distinct from the epitope on IL-2Rb bound by IL-2. Alternatively, IL-15 may bind to a separate receptor subunit (such as IL-15Ra) that is not blocked by HuMikb1, and this binding may partially compensate for the inhibitory effect of the HuMikb1 antibody. The second antibody used in these studies against the IL-2Rb subunit was mAb 341, which does not inhibit IL-2 from binding the IL-2Rb chain. 20 As expected, Tf-1b proliferation to IL-2 or IL-15 is not affected by the addition of this mAb 341 (Fig. 2) .
These blocking studies with HuMikb1 and mAb 341 were repeated on OKT3 blasts expressing high The responses to IL-2 (A) and IL-15 (B) were analysed in the presence of media alone (W), MOPC21 isotype control antibody (w), mAb 341, a non-inhibitory anti-IL-2Rb antibody (R), anti-IL-2Ra antibody GL439 (r), human serum, to serve as a control (Q), and the humanized anti-IL-2Rb antibody HuMikb1 (q). The final concentration of each antibody in the well was 50 mg/ml. An appropriate range of cytokine concentrations was selected for each experiment based on the EC50 values for IL-2 and IL-15. HuMikb1 completely inhibits IL-2 stimulated proliferation, but blocks only approximately 65% of the IL-15 stimulated response. affinity IL-2R (Fig. 3) . OKT3 blasts are a heterogeneous population of activated T cells, and are comparable to PHA blasts in their responses to IL-2 and IL-15 and in their expression of IL-2 receptor components (data not shown). As expected, the anti-IL-2Ra mAb GL439 inhibited 95% of proliferation mediated via high affinity IL-2 receptors stimulated by low concentrations of IL-2 (Fig. 3A) , but did not alter the response to IL-15 (Fig. 3B) . Surprisingly, mAb 341 blocked approximately 20% of the response of OKT3 blasts to IL-15, although this antibody does not block IL-2 binding and did not affect the response of OKT3 blasts to IL-2 ( HuMikβ1 the affinity of IL-2 for the high affinity trimolecular abg c complex (K d = 10 pM), so that this Mikb1 antibody does not inhibit IL-2-stimulated responses of high affinity receptor bearing cells. 22 This observation is confirmed in our studies here, however an important difference is noted in the IL-15 responses. HuMikb1 did block approximately 80% of the IL-15-stimulated proliferation of these OKT3 blasts, despite the fact that these T cells express high affinity IL-15R, as determined by Scatchard binding analyses. 10, 16 Therefore, IL-15 appears to utilize its IL-15Ra subunit differently from the way that IL-2 utilizes its IL-2Ra subunit on OKT3 blasts. IL-2Ra combines with the IL-2Rbg c complex to convert intermediate affinity receptors into high affinity IL-2R. IL-15Ra, which alone can bind IL-15 with high affinity, appears not to serve this same type of ''affinity converting'' function for the bg c complex because the IL-15 response (but not the IL-2 response) on OKT3 blasts can be partially blocked by HuMikb1. The fact that HuMikb1 antibody does not completely inhibit the IL-15 response by OKT3 blasts, suggests that either IL-15 interacts with an epitope on the IL2Rb chain distinct from that of IL-2, or that perhaps the IL-15Ra can overcome a portion of the blocking by HuMikb1.
Increasing the concentration of HuMikb1 anti-IL-2Rb blocking antibody saturates the inhibitory response, but does not completely abrogate IL-15-stimulated proliferation
The data illustrated in Figures 2 and 3 were generated using varying concentrations of cytokine with a fixed concentration of blocking antibody (50 mg/ml), and did not result in complete blocking of proliferation under some conditions. In order to verify the reliability of these results, the converse experiment also needed to be performed using a fixed concentration of cytokine and varying dilutions of antibody. The data suggested that IL-15 and IL-2 might bind to the extracellular portion of the IL-2Rb chain differently, and hence it was important to determine if the IL-15 response could be completely inhibited merely by increasing the concentration of blocking antibody relative to the concentration of cytokine. In order to test this hypothesis, PHA blasts and Tf-1b cells were tested under conditions with titrated concentrations of blocking antibodies and a constant concentration of cytokine, approximately equal to the EC 50 value. By increasing the concentration of antibody relative to cytokine, we hoped to show whether the partial inhibition of IL-15-stimulated proliferation could be increased to 100% inhibition.
As indicated by the representative experiment with Tf-1b cells shown in Figure 4 , HuMikb1 antibody inhibits nearly all of the IL-2 stimulated proliferation. Maximal inhibition is reached in the presence of approximately 5 mg/ml of HuMikb1, as indicated by the plateau in the inhibition curve (Fig. 4A) . In five separate experiments, the mean inhibition of IL-2 stimulation was 92.2% 2 2.5%, under these conditions (Table 2 ). In contrast, the proliferative response to IL-15 by Tf-1b cells is only partially abrogated by HuMikb1 antibody, and the inhibition curve also plateaus at approximately 5 mg/ml of HuMikb1 antibody (Fig. 4B) . In five separate experiments, the mean inhibition was 57.9% 2 3.7%. These data indicate that increasing the concentration of HuMikb1 blocking antibody will not result in greater inhibition of IL-15-stimulated proliferation, and therefore suggest The responses to IL-2 (A) and IL-15 (B) were analysed in the presence of media alone (W), MOPC21 isotype control antibody (w), mAb 341, a non-inhibitory antibody against IL-2Rb (R), anti-IL-2Ra antibody GL439 (r), human serum, as a control (Q), and the humanized anti-IL-2Rb antibody HuMikb1 (q). The final concentration of each antibody in the well was 50 mg/ml. An appropriate range of cytokine concentrations was selected for each experiment based on the EC50 values for IL-2 and IL-15. HuMikb1 did not affect IL-2 stimulated proliferation, but suppressed approximately 80% of the IL-15 stimulated proliferation. Anti-IL2Ra antibody GL439 blocked 95% of IL-2 stimulated proliferation, but did not affect IL-15 stimulation. The GL439 data are difficult to visualize in panel B, as the control data and the data with the GL439 antibody are virtually superimposed. The largest error bar in B at the greatest concentration of IL-15 coincides with the GL439 data point. mAb 341, which does not block IL-2 binding to the IL-2Rb chain, did not alter IL-2 stimulated proliferation, but did inhibit approximately 20% of IL-15-stimulated proliferation. Tf-1b cells were stimulated with 50 pM IL-2 (A) or 150 pM IL-15 (B), and incubated with increasing concentrations of various antibodies. Purified MOPC21 antibody (W) was the isotype control for anti-IL-2Ra antibody GL439 (w). Human serum (R) served as the isotype control for the humanized anti-IL-2Rb antibody HuMikb1 (r). MOPC21 ascites (Q) was the isotype control for mAb 341 ascites, a non-inhibitory anti-IL-2Rb antibody (q). HuMikb1 inhibits 92.2% 2 2.5 (n = 5, P Q 0.0001) of IL-2-stimulated proliferation, but blocks only 57.9% 2 3.7 (n = 5, P Q 0.0001) of the IL-15-stimulated response. Both inhibition curves reach a plateau at approximately 5 mg/ml. Statistical analyses were performed using one-way ANOVA of the data points at 7.5 mg/ml of antibody. P values were determined from least significant difference (LSD) comparisons with controls.
PHA blasts (Fig. 5A) . However, 341 did significantly inhibit proliferation activated by IL-15 (35.4% 2 2.3%, n = 3), demonstrating again that IL-15 might bind to the IL-2Rb chain differently than IL-2 does (Fig. 5B) .
As expected, HuMikb1 does not inhibit proliferation of PHA blasts stimulated by low concentrations of IL-2 (Fig. 5A) . However, at antibody concentrations greater than 10 mg/ml, we observed a small degree of inhibition (21.9 2 3.5%, n = 7). In contrast, HuMikb1 inhibits 88.5% 2 1.6% (n = 7) of IL-15-stimulated responses by PHA blasts (Fig. 5B) . This occurs despite expression of high affinity IL-15 binding by these cells, 4, 16 suggesting that the IL-15Ra chain and the IL-2Ra serve distinct roles for ligand binding in their respective high affinity receptor complexes. The results from the experiments in Figure 5 are similar for either PHA blasts or KIT225 cells, an IL-2 dependent human T cell line (data not shown).
Antibody against IL-2 does not inhibit IL-15 stimulated responses by PHA blasts
Anti-IL-15 antibody M111 and polyclonal anti-IL-2 rabbit anti serum were used to confirm that the responses documented here using PHA blasts were truly mediated by IL-15, and not due to the induction of IL-2 as a secondary cytokine. Proliferation of PHA blasts in response to IL-2 is blocked only by the anti-IL-2 antiserum, and not the anti-IL-15 antibody, M111 (Fig. 6) . Likewise, IL-15 stimulated prolieration is inhibited by anti-IL-15, and not by anti-IL-2 antibody. Similar results have been documented using Tf-1b cells (Farner et al., submitted) .
DISCUSSION
Although IL-2 and IL-15 share many functional responses, we noted that often a greater quantity of IL-15 was required to stimulate the same level response as IL-2. While this observation might be explained merely by a lower specific activity of the IL-15 reagent compared to IL-2, this possibility seemed unlikely in that cytotoxicity dose-response curves for IL-2 and IL-15 using these same reagent stocks were not different from each other. 24 A more intriguing hypothesis to explain these proliferation dose-response differences is that IL-2 and IL-15 may bind to extracellular portions of shared receptor components differently. In order to establish these functional distinctions fully, cells bearing high affinity IL-2R (that is, PHA and OKT3 blasts), and cells bearing intermediate affinity IL-2R (Tf-1b cells) were subjected to proliferative assays containing IL-2, IL-15 or F42K. Regardless of whether the responding cells expressed high affinity or intermediate affinity receptors, the EC 50 that IL-15 physically interacts differently with the IL-2Rb chain than IL-2 does.
These same experiments were repeated using PHA blasts and a representative experiment is shown in Figure 5 . As expected, anti-IL-2Ra antibody GL439 blocked 93.6% 2 2.7% (n = 7) of the IL-2 stimulated response (Fig. 5A ), but did not alter IL-15 stimulated proliferation (inhibition of −3.4% 2 4.4%, n = 7) (Fig. 5B, Table 2 ). Anti-IL-2Rb antibody 341, which does not block IL-2 binding to the IL-2Rb chain, also did not alter IL-2 stimulated proliferation of these value for IL-15 was always significantly higher than that of IL-2 (Table 1 ). This result indicated that more IL-15 than IL-2 is required to activate half-maximal proliferation of each of these cell types, independent of IL-2Ra expression.
The IL-2 variant, F42K, allowed us to clarify further the influence of IL-2Ra expression in those assays involving cells with high affinity IL-2R, as F42K does not bind to this subunit. If the quantitative differences between IL-2 and IL-15 responses were due to receptor differences, then an obvious candidate for mediating these differences would be the IL-2Ra chain since IL-15 does not utilize this subunit. If the IL-2Ra chain were the sole factor accounting for the differential proliferative responses to IL-2 and IL-15, then the results with F42K (which like IL-15 does not utilize the IL-2Ra molecule) should mimic those with IL-15. However, the mean EC 50 for IL-15 was significantly higher than that of F42K for PHA blasts and Tf-1b cells, (P = 0.0004 and 0.05, respectively), indicating that the IL-2Ra chain was not the only determinant influencing the quantitatively distinct proliferative responses induced by IL-2 and IL-15. This is consistent with previously published data using the inhibitory anti-IL-2Ra mAb, GL439. Inclusion of mAb GL439 had no influence on IL-15-stimulated proliferation, but inhibited the IL-2 response, resulting in a shift of the IL-2 dose-response curve to the right, although not as far to the right as the IL-15 dose-response curve. 16 This again suggested that other determinants, besides the IL-2Ra subunits, were affecting this quantitative response differential.
Previously published molecular data suggest that IL-2Rb and g c interact more strongly with IL-2 than with IL-15. 16 Co-immunoprecipitation experiments have proven that the interactions between IL-2, IL-2Rb and g c are sufficiently strong to allow co-precipitation of this bg c complex from intermediate affinity receptor bearing YT cells when incubated with IL-2. 20 However, IL-15 interacts more weakly with the bg c complex so that immunoprecipitates with anti-IL-2Rb antibodies do not precipitate g c along with b in the presence of IL-15. 16 Therefore, IL-15 may not interact as strongly with the bg c complex as IL-2 does, potentially resulting in the functional differences reported here. Further binding assays to determine association and dissociation constants for IL-2 and IL-15 need to be performed in order to fully clarify these differences. Taken together with the proliferative results using F42K and anti-IL-2Ra antibodies on both high affinity and intermediate affinity receptor bearing cells, it appears that IL-15 may not interact as strongly with the bg c complex as does IL-2, independent of the influence of the IL-2Ra molecule. This weaker extracellular interaction may have functional significance which impacts on proliferative response.
Additional experiments examined the ability of antibodies directed against the IL-2Rb chain to affect IL-2 and IL-15-stimulated proliferation of cells bearing high or intermediate affinity IL-2R. The anti-IL-2Rb antibody, HuMikb1 did not influence the response of PHA blasts to IL-2, but did block proliferation of Tf-1b cells in response to IL-2. In contrast, IL-15-stimulated proliferation of both PHA blasts and Tf-1b cells was blocked by HuMikb1, although not completely. In addition, the mAb 341, which does not inhibit the response to IL-2, had no effect on IL-15 stimulated proliferation of Tf-1b cells, but was able to inhibit a small portion of the proliferation of PHA blasts stimulated by IL-15. Not only do these data indicate distinctions between binding of the IL-2Rb chain by IL-15 and IL-2, but they also suggest that the IL-15Ra chain functions differently than its IL-2Ra counterpart within their respective high affinity IL-15 PHA blasts were stimulated with 20 pM IL-2 (A) or 4 nM IL-15 (B), and incubated with increasing concentrations of various antibodies. Purified MOPC21 antibody (W) was the isotype control for anti-IL-2Ra antibody GL439 (w). Human serum (R) served as the isotype control for the humanized anti-IL-2Rb antibody HuMikb1 (r). MOPC21 ascites (Q) was the isotype control for mAb 341 ascites, a non-inhibitory anti-IL-2Rb antibody (q). HuMikb1 inhibited 21.9% 2 3.5 (n = 7) of IL-2-stimulated proliferation only at the highest concentrations of antibody. However, HuMikb1 blocked 88.5% 2 1.6 (n = 7, P Q 0.0001) of IL-15 stimulated proliferation. Anti-IL-2Ra antibody GL439 blocked 93.6% 2 2.7 (n = 7, P Q 0.0001) of IL-2 stimulated proliferation, but did not affect IL-15 stimulation. mAb341, which does not block IL-2 binding to the IL-2Rb chain, did not alter IL-2 stimulated proliferation, but did inhibit 35.4% 2 2.3 (n = 3, P Q 0.0001) of IL-15-stimulated proliferation. Statistical analyses were performed using one-way ANOVA of the data points at 7.5 mg/ml of antibody. P values were determined from least significant difference (LSD) comparisons with controls.
These blocking data are also consistent with the hypothesis that different populations of receptors which interact with IL-2 and IL-15 may be simultaneously present on the same cell surface. As has been shown previously, IL-2 receptors exist in two forms on activated T cells: an abundance of low affinity receptors (IL-2Ra alone) and a few high affinity receptors (trimolecular abg c complexes). All the IL-2 receptors capable of signalling in response to IL-2 on these IL-2Ra expressing cells have high affinity for IL-2 because the IL-2Ra chain is expressed in excess. [5] [6] [7] In contrast, if the IL-15Ra chain were the limiting subunit required for high affinity binding, then two populations of IL-15 receptors might exist simultaneously on the cell surface which are each capable of signal transduction: high affinity IL-15Rabg c complexes, and intermediate affinity bg c complexes (shown schematically on Tf-1b cells in Fig. 7 ). While IL-15Ra alone is capable of binding IL-15 with high affinity, it does not appear to have signalling capabilities.
9,10 If these two populations of IL-15 receptors were present on a cell, then HuMikb1 would presumably block the intermediate affinity IL-15R (i.e. the IL-2Rbg c complexes), but not the high affinity IL-15R, and thereby would never be able to block 100% of IL-15-stimulated proliferation of any cell type expressing the IL-15Ra chain, including OKT3 blasts, PHA blasts, and Tf-1b cells, even at saturating concentrations of antibody, as the data indicate in Figures 4 and 5 . In a heterogeneous population of cells such as OKT3 blasts or PHA blasts, we cannot distinguish whether these two types of IL-15 PHA blasts were incubated with IL-2 or IL-15 and 10 mg/ml of anti-IL-2 (polyclonal rabbit anti-IL-2 antibody) or anti-IL-15 antibody mAb M111.
and IL-2 receptor complexes. Intermediate affinity IL-2R complexes (bg c ) are blocked by HuMikb1 antibody, while high affinity IL-2R complexes (abg c ) are not. The IL-2Ra chain converts the intermediate affinity bg c complex to the high affinity IL-2R, and thereby is not blocked by HuMikb1 antibody. 22 Since IL-15 stimulation is blocked by HuMikb1 on cells expressing high affinity IL-15 receptors, we conclude that the IL-15Ra is not serving the same purpose on the cell surface as IL-2Ra does in its high affinity receptor. The IL-15Ra chain can bind IL-15 with high affinity all alone, however, this is not believed to be a signal-transducing receptor. If IL-15Ra were to interact with the IL-2Rabgc complex, then this four-part complex would be expected to bind IL-15 with high affinity and also transduce a signal to the cell. This high affinity IL-15 receptor might not be blocked by HuMikb1. However, this receptor may be inhibited by mAb 341, as suggested by the blocking data from the experiment presented in Figure 5 .
The upper panel depicts IL-2 and IL-15 receptors on the surface of Tf-1b cells. This is a homogeneous, cloned cell line, and presumably all cells express the same receptor subunits. The intermediate affinity IL-15 and IL-2 receptors (bgc) would be blocked by HuMikb1, consistent with the abrogation of IL-2 stimulation seen in Figure 4A . However, the high affinity IL-15 receptors (IL-15Rabgc) on these same cells may not be blocked by HuMikb1. Therefore, even by increasing the HuMikb1 concentration to a saturating level, one could inhibit some of the IL-15 stimulation, but never completely inhibit IL-15 stimulation of these Tf-1b cells, as observed in Figure 4B . The expression of IL-15Ra on the surface of these cells is postulated, based upon high affinity IL-15 binding observed with Scatchard analysis.
Diagram is not drawn to scale. 12,25 These methods are relatively insensitive however, and do not allow quantitation of IL-15Ra protein levels in comparison to IL-2Ra. At present, no anti-IL-15Ra antibody exists with sufficient affinity to allow quantitative detection of surface IL-15Ra.
The hypothesis proposed above still does not explain why mAb 341, an antibody directed against the IL-2Rb chain that does not inhibit the response to IL-2, is able to partially block IL-15-stimulated proliferation of cells bearing high affinity IL-2R complexes (PHA blasts) but not cells bearing intermediate affinity IL-2R complexes. Perhaps the presence of the IL-2Ra inhibits the ability of IL-15Ra molecules to interact with and signal through the shared bg c signalling complex. It is possible that IL-15 could still stimulate its intermediate affinity bg c receptor, even if the IL-2Ra chain were also associated with that same bg c complex (Fig. 7) . Such an association with the IL-2Ra chain might alter the conformation of the IL-2Rb chain so that inhibition of IL-15 stimulation by mAb 341 is facilitated. Since IL-2 stimulation is not affected by the addition of mAb 341, this again supports the idea that IL-15 binds the IL-2Rb chain differently than IL-2 does. The blocking data with mAb 341 are consistent with this hypothesis. Approximately 20% of the IL-15-stimulated response was inhibited by mAb 341, compatible with the idea that only a minority (020%) of IL-15 receptors on PHA blasts contain the IL-15Ra molecule and would be affected by IL-2Ra (the IL-2Ra + IL-15Ra + bg c complex; second from the right in the lower panel of Fig. 7) , while the remainder are intermediate affinity IL-15R (i.e. IL-2Rbg c ) complexes, not influenced in their IL-15 response by the presence of IL-2Ra, (far right, lower panel of Fig. 7 ). Further testing of these hypotheses will require a sensitive method for directly detecting and quantitating IL-15Ra protein on the surface of these cells.
Taken together, the data presented here indicate that quantitative distinctions do exist in proliferative responses stimulated by IL-2 and IL-15, and these may be due to different physical binding interactions with the IL-2Rb chain. These data support the conclusion that IL-2Ra maintains a different role than that of the IL-15Ra chain in their respective high affinity receptor complexes. In addition, these results support the possibility that two different types of signal transducing IL-15 receptors may be present simultaneously on the surface of a cell, such as a PHA blast. Further studies are warranted to determine the biological significance of these physical differences between IL-2 and IL-15.
MATERIALS AND METHODS
Cell lines
Tf-1 cells were established from a patient with erythroleukemia, and require GM-CSF or IL-3 for growth in vitro. 13 Tf-1b cells were generated by infecting the Tf-1 human myelomonocytic leukaemia cell line with a retroviral vector containing the IL-2Rb gene.
14 Tf-1b cells were maintained in RPMI complete medium consisting of RPMI 1640 (Bio Whittaker, Walkersville, MD) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM -glutamine, and 25 mM HEPES (pH 7.4). Tf-1b cultures were also supplemented with 5 ng/ml GM-CSF or 50-100 U/ml IL-2. Cells were maintained by culturing at 1-10 × 10 5 cells/ml, and splitting cultures every 2-3 days.
Generation of blast cell populations
Fresh peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by centrifugation over a Ficoll-Hypaque density gradient. All volunteer donors signed informed consent documents approved by the UW Committee for the Protection of Human Subjects. OKT3 blasts were established by stimulating fresh PBMC for 4 days with surface immobilized OKT3 (anti-CD3) antibody (Ortho Diagnostics, Raritan, NJ) in RPMI complete medium with 10% human serum substituted for FBS, as described previously.
15 PHA blasts were established by culturing fresh PBMC in RPMI complete medium with 1 mg/ml of purified phytohaemagglutinin (PHA; Burroughs Wellcome Co., Greenville, NC), and 10% human serum (Pel-Freeze, Brown Deer, WI) Substituted for FBS. PHA blasts were cultured for 4 days in PHA. For some experiments these were subsequently cultured in complete medium with 100 U/ml IL-2 for 3-7 days. These treatments to generate OKT3 blasts and PHA blasts resulted in populations consisting predominantly of T cells (q95% CD3
+ by flow cytometry, data not shown). By Scatchard binding analysis PHA blasts and OKT3 blasts express high affinity IL-2 receptors and high affinity IL-15 receptors.
4,16
Cytokines
Recombinant human IL-2 with a specific activity of 1. (Nutley, NJ) . The concentration of the stock F42K was determined by dividing the OD at 280 nm by the extinction coefficient (0.665, determined experimentally for IL-2).
Antibodies
The murine monoclonal antibody (mAb) 341 (IgG1), provided by Dr R. Robb (Oncotherapeutics Inc.), reacts with the IL-2Rb chain, but does not block binding of IL-2. 20 Both ascites and purified preparations of mAb 341 were utilized. Murine monoclonal antibody GL439 (IgG1), also provided by Dr R Robb, recognizes IL-2Ra and inhibits IL-2 binding to high affinity receptors. 21 Murine antibody MOPC21 (IgG1) was used as an isotype control in both purified and ascites preparations (Sigma, St Louis, MO). The humanized form of the mouse monoclonal antibody Mikb1 (HuMikb1) is directed against the IL-2Rb chain and blocks IL-2 binding to intermediate affinity IL-2 receptors. 22, 23 HuMikb1 was generously provided by Dr J. Hakimi (Hoffman La Roche, Nutley, NJ). Human serum (Pel-Freeze, Brown Deer, WI) was used as the control for HuMikb1. M111 is a murine anti-human IL-15 antibody kindly provided by M. LarsonMarlowe at Genzyme Corporation (Cambridge, MA). Polyclonal rabbit sera against IL-2 was also provided by Dr R. Robb (Oncotherapeutics Inc.).
In vitro proliferative assay
Responder cells (1 × 10 4 ) were added to triplicate wells of 96-well microtitre plates in a final volume of 200 ml of RPMI 1640 complete medium and increasing concentrations of IL-2, IL-15, or F42K in the presence or absence of monoclonal antibody at a final concentration of 50 mg/ml, unless otherwise noted. Cells were incubated for 48 h at 37°C with 5% CO2, followed by 12-16 h of pulse labelling with 1 mCi of [ 3 H]thymidine per well. Cultures wre harvested onto glass fibre filters using a 96-well Packard FilterMate cell harvester (Packard Instrument Company, Meriden, CT). Dry filters were then counted for 5 min by gas ionization detection on a Packard Matrix9600 direct beta counter (Packard Instrument Company, Meriden, CT). Values are reported as total counts measured in 5 min. EC50 values (effective concentration of cytokine necessary to achieve 50% of maximal stimulation) were calculated using the ALLFIT program, provided by J. Rossio at the National Cancer Institute, Frederick, MD. Blocked one-way analysis of variance (1-way ANOVA) was performed by Dr M. Lindstrom from the Department of Biostatistics at the University of Wisconsin, Madison. Multiple stimuli within each experimental group were further compared using the least significant difference (LSD) method.
